AXL as a Target in Breast Cancer Therapy

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

(2019) Hirokazu Taniguchi et al.   Nature Communications

Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas

(2019) Yoko Tsukita et al.   Molecular Cancer

Ampelopsins A and C Induce Apoptosis and Metastasis through Downregulating AxL, TYRO3, and FYN Expressions in MDA-MB-231 Breast Cancer Cells

(2019) Cheng Huang et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Quinolone antibiotic derivatives as new selective Axl kinase inhibitors

(2019) Li Tan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Pan-TAM tyrosine kinase inhibitor BMS-777607 enhances anti-PD-1 mAb efficacy in a murine model of triple-negative breast cancer

(2019) Canan Kasikara et al.   CANCER RESEARCH

Effect of therapeutic GAS6/AXL inhibition of tumor and stromal cells on DNA damage and response to chemotherapy in ovarian cancer.

(2019) Mary M Mullen et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel human anti‐ AXL monoclonal antibody attenuates tumor cell migration

(2019) Duan Yanting et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells

(2019) Donghwa Kim et al.   Cell Death & Disease

Acquired resistance mechanisms to afatinib in HER 2 ‐amplified gastric cancer cells

(2019) Takahiro Yoshioka et al.   CANCER SCIENCE

Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation

(2019) Markus Lauter et al.   Cell Communication and Signaling

Therapeutic AXL inhibition of tumor and tumor microenvironment stromal cells improves response to chemotherapy in ovarian cancer

(2019) M.M. Mullen et al.   GYNECOLOGIC ONCOLOGY

MicroRNA‐139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL

(2019) Robert K. Nam et al.   PROSTATE

Axl signaling is an important mediator of tumor angiogenesis

(2019) Mai Tanaka et al.   Oncotarget

Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma

(2018) Hirokazu Sadahiro et al.   CANCER RESEARCH

A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers

(2018) Jing Wei et al.   CELLULAR IMMUNOLOGY

TP-0903 inhibits neuroblastoma cell growth and enhances the sensitivity to conventional chemotherapy

(2018) Sanja Aveic et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung.

(2018) Murray Yule et al.   JOURNAL OF CLINICAL ONCOLOGY

The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression

(2018) Marie-Anne Goyette et al.   Cell Reports

Abstract 827: Anti-tumor efficacy of BA3011, a novel Conditionally Active Biologic (CAB) anti-AXL-ADC

(2018) Leslie L. Sharp et al.   CANCER RESEARCH

Abstract 3759: Characterization of INCB081776, a potent and selective dual AXL/MER kinase inhibitor

(2018) Margaret Favata et al.   CANCER RESEARCH

Abstract 832: An AXL-specific antibody-drug conjugate shows preclinical anti-tumor activity in non-small cell lung cancer, including EGFR-inhibitor resistant NSCLC

(2018) Louise A. Koopman et al.   CANCER RESEARCH

Comprehensive Characterization of Cancer Driver Genes and Mutations

(2018) Matthew H. Bailey et al.   CELL

Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

(2018) Allison M. Claas et al.   Cellular and Molecular Bioengineering

A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors.

(2018) Jordi Rodon Ahnert et al.   JOURNAL OF CLINICAL ONCOLOGY

MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents

(2018) Nellie K McDaniel et al.   MOLECULAR CANCER THERAPEUTICS

An integrated approach of bioinformatic prediction and in vitro analysis identified that miR-34a targets MET and AXL in triple-negative breast cancer

(2018) Shadan Hajalirezay Yazdi et al.   CELLULAR & MOLECULAR BIOLOGY LETTERS

Soluble AXL is ubiquitously present in malignant serous effusions

(2018) Karine Flem Karlsen et al.   GYNECOLOGIC ONCOLOGY

Therapeutic activity of DCC‐2036, a novel tyrosine kinase inhibitor, against triple‐negative breast cancer patient‐derived xenografts by targeting AXL/MET

(2018) Yingying Shen et al.   INTERNATIONAL JOURNAL OF CANCER

Dynamics of Axl Receptor Shedding in Hepatocellular Carcinoma and Its Implication for Theranostics

(2018) Elisa Holstein et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non–Small Cell Lung Cancer Cells

(2018) Kei Namba et al.   MOLECULAR CANCER RESEARCH

Stromal Gas6 promotes the progression of premalignant mammary cells

(2018) Angelica M. Gomes et al.   ONCOGENE

Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy

(2018) Sutapa Sinha et al.   Oncotarget

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms

(2017) Peter P. Ruvolo et al.   HAEMATOLOGICA

Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer

(2017) Anna Di Benedetto et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor

(2017) Toni M. Brand et al.   Science Signaling

Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis

(2017) Mirko Dengler et al.   Oncotarget

Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival

(2017) Julia Onken et al.   Oncotarget

Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity

(2017) Stanley G. Kimani et al.   Scientific Reports

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms

(2017) Peter P. Ruvolo et al.   HAEMATOLOGICA

The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor

(2017) Toni M. Brand et al.   Science Signaling

Requirement of Gamma-Carboxyglutamic Acid Modification and Phosphatidylserine Binding for the Activation of Tyro3, Axl, and Mertk Receptors by Growth Arrest-Specific 6

(2017) Ke Geng et al.   Frontiers in Immunology

Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease and cancer

(2016) R B Birge et al.   CELL DEATH AND DIFFERENTIATION

Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis

(2016) Wilhem Leconet et al.   CLINICAL CANCER RESEARCH

Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies

(2016) Mihalis S. Kariolis et al.   JOURNAL OF CLINICAL INVESTIGATION

Expression of Axl and its prognostic significance in human breast cancer

(2016) Gaoyuan Jin et al.   Oncology Letters

Reprogramming the immunological microenvironment through radiation and targeting Axl

(2016) Todd A. Aguilera et al.   Nature Communications

Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance

(2016) M. A. Miller et al.   Cancer Discovery

A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer

(2016) Adrian G. Sacher et al.   Oncotarget

Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells

(2016) M Vouri et al.   Oncogenesis

Epithelial-Mesenchymal Transition and Breast Cancer

(2016) Yanyuan Wu et al.   Journal of Clinical Medicine

AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

(2015) Moshe Elkabets et al.   CANCER CELL

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

(2015) M. P. Mak et al.   CLINICAL CANCER RESEARCH

Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia

(2015) I-K Park et al.   LEUKEMIA

Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth

(2015) Francesca Zanconato et al.   NATURE CELL BIOLOGY

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

(2015) L Zhou et al.   ONCOGENE

A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification

(2015) Matteo Dugo et al.   Oncotarget

Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche Activation, Epithelial Reversion, and Metastatic Colonization

(2015) Yaiza del Pozo Martin et al.   Cell Reports

Soluble AXL: A Possible Circulating Biomarker for Neurofibromatosis Type 1 Related Tumor Burden

(2015) Gunnar Johansson et al.   PLoS One

Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells

(2015) Maeva Dufies et al.   Oncotarget

Axl as a mediator of cellular growth and survival

(2015) Haley Axelrod et al.   Oncotarget

Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma

(2014) Fei Xu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway

(2014) Maolan Li et al.   CANCER LETTERS

AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs

(2014) C. Wilson et al.   CANCER RESEARCH

AXL Mediates Resistance to Cetuximab Therapy

(2014) T. M. Brand et al.   CANCER RESEARCH

Axl receptor tyrosine kinase expression in breast cancer

(2014) Timothy M D'Alfonso et al.   JOURNAL OF CLINICAL PATHOLOGY

Axl Phosphorylates Elmo Scaffold Proteins To Promote Rac Activation and Cell Invasion

(2014) Afnan Abu-Thuraia et al.   MOLECULAR AND CELLULAR BIOLOGY

PhosphoSitePlus, 2014: mutations, PTMs and recalibrations

(2014) Peter V. Hornbeck et al.   NUCLEIC ACIDS RESEARCH

Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET

(2014) Erinn B. Rankin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phyllodes tumor of the breast: role of Axl and ST6GalNAcII in the development of mammary phyllodes tumors

(2014) Dongliang Ren et al.   TUMOR BIOLOGY

Activation of HER3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors: Suggestion of Combination Therapy

(2014) Robert Torka et al.   NEOPLASIA

TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase

(2013) X. Wang et al.   CANCER RESEARCH

AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer

(2013) P. D. Dunne et al.   CLINICAL CANCER RESEARCH

AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival

(2013) Smita Salian-Mehta et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells

(2013) M K Asiedu et al.   ONCOGENE

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy

(2013) W Leconet et al.   ONCOGENE

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells

(2013) A. S. Meyer et al.   Science Signaling

Differential Expression of Axl and Correlation with Invasion and Multidrug Resistance in Cancer Cells

(2012) Yongfu Zhao et al.   CANCER INVESTIGATION

ABL Regulation by AXL Promotes Cisplatin Resistance in Esophageal Cancer

(2012) J. Hong et al.   CANCER RESEARCH

Phosphoproteomics Identifies Driver Tyrosine Kinases in Sarcoma Cell Lines and Tumors

(2012) Y. Bai et al.   CANCER RESEARCH

An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

(2012) L. A. Byers et al.   CLINICAL CANCER RESEARCH

Axl is essential for VEGF-A-dependent activation of PI3K/Akt

(2012) Guo-Xiang Ruan et al.   EMBO JOURNAL

PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS

(2012) Matthew P. Stokes et al.   MOLECULAR & CELLULAR PROTEOMICS

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays

(2012) T S Gujral et al.   ONCOGENE

Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer

(2012) R M A Linger et al.   ONCOGENE

Axl glycosylation mediates tumor cell proliferation, invasion and lymphatic metastasis in murine hepatocellular carcinoma

(2012) Ji Li   WORLD JOURNAL OF GASTROENTEROLOGY

Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA

(2011) Mark Mackiewicz et al.   BREAST CANCER RESEARCH AND TREATMENT

Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer

(2011) G Mudduluru et al.   ONCOGENE

Design, Synthesis, and Biological Evaluation of a Series of Novel AXL Kinase Inhibitors

(2011) Alexis Mollard et al.   ACS Medicinal Chemistry Letters

PMA up-regulates the transcription of Axl by AP-1 transcription factor binding to TRE sequences via the MAPK cascade in leukaemia cells

(2010) Giridhar Mudduluru et al.   BIOLOGY OF THE CELL

Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma

(2010) R. Liu et al.   BLOOD

R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer

(2010) S. J. Holland et al.   CANCER RESEARCH

Myeloid Zinc Finger 1 Induces Migration, Invasion, and In vivo Metastasis through Axl Gene Expression in Solid Cancer

(2010) G. Mudduluru et al.   MOLECULAR CANCER RESEARCH

AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma

(2010) M Z Xu et al.   ONCOGENE

An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies

(2010) X Ye et al.   ONCOGENE

Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer

(2010) K Vuoriluoto et al.   ONCOGENE

Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6

(2009) S. Loges et al.   BLOOD

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis

(2009) Y Li et al.   ONCOGENE

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

(2009) C. Gjerdrum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The human receptor tyrosine kinase Axl gene - promoter characterization and regulation of constitutive expression by Sp1, Sp3, and CpG methylation

(2008) Giridhar Mudduluru et al.   BIOSCIENCE REPORTS

Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia

(2008) Chih-Chen Hong et al.   CANCER LETTERS

AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression

(2008) Y.-X. Zhang et al.   CANCER RESEARCH

Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1

(2008) K-Y Tai et al.   ONCOGENE